Think of Type 2 Diabetes as a puzzle where not every patient has the same pieces. Some people have a hidden 'fire' of inflammation in their blood that makes the disease much more dangerous. This work identifies that specific group of people early on so doctors can put out the fire before it causes heart attacks or kidney failure.
Type 2 Diabetes is too diverse for a one-size-fits-all treatment, making it impossible to predict which patients will suffer catastrophic complications like heart attacks or kidney failure.
A multi-omics diagnostic strategy to identify an inflammatory T2D endotype and a Phase 2 clinical trial for NLRP3 Inflammasome anti-inflammatory therapy.
If you are a drug developer dealing with high failure rates in general diabetes trials — this project developed a method to identify an 'Inflammatory-mediated T2D' endotype that allows for precise patient stratification. This ensures the right anti-inflammatory therapy reaches the 10 to 15% of patients who actually respond to it.
If you are a precision medicine lab dealing with the inability to predict which diabetes patients will develop complications — this project developed a multi-omics screening process using blood monocytes. This allows you to offer a diagnostic test that predicts the risk of stroke or nephropathy at the time of diagnosis.
If you are a clinic network dealing with the high cost of treating advanced diabetic complications — this project developed a clinical trial for NLRP3 Inflammasome therapy. This enables a shift toward preventative, tailored care that reduces long-term disability and mortality.
Based on available project data, no pricing or cost information for the diagnostic or therapeutic tools is provided.
The project uses a multi-omics strategy and a Phase 2 clinical trial, suggesting a path toward industrial medical application, though specific scaling metrics are not listed.
Based on available project data, there is no mention of specific patents or licensing agreements currently in place.
It integrates at the point of diagnosis by adding inflammatory parameter measurements to the standard T2D screening process.
The project period runs from 2023-01-01 to 2027-12-31, indicating that final results and trial outcomes will be available toward the end of 2027.
The consortium is research-heavy, consisting of 14 partners across 7 countries. While 10 members are from universities or research institutes, there is a 14% industry presence (2 companies), indicating a transition from academic discovery toward commercial application. The coordination by INSERM (France) ensures strong clinical backing.
Contact INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Contact us to explore licensing opportunities for the inflammatory T2D endotype biomarkers.
